NanoViricides, Inc. announced that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy. Several of the anti-Herpes nanoviricides(R) demonstrated a dose-dependent maximal inhibition of Herpes virus infectivity in a cell culture model. Almost complete inhibition of the virus production was observed at clinically usable concentrations. These studies employed the H129 strain of herpes simplex virus type 1 (HSV-1). H129 is an encephalitic strain that closely resembles a clinical isolate; it is known to be more virulent than classic HSV-1 laboratory strains. The H129 strain will be used in subsequent animal testing of nanoviricides. This anti-HSV program is designed for the development of an effective anti-herpes nanoviricide drug for the treatment of cold sores or genital herpes simplex virus infections. The Company plans to develop this drug as a skin cream or ointment formulation for external application. The nanoviricides(R) mechanism of action is believed to mimic a natural host cell receptor by which the virus binds and infects cells; binding of a nanoviricide nanomicelle to the virus renders it non-infectious. A nanoviricide would thus stop the spread of the viral infection to new uninfected cells. This mechanism is different from that of currently available anti-Herpes drugs and therefore is expected to be complementary to that of the current drugs. Dr. Rosenthal's laboratory has developed an improved mouse model of skin-infection by HSV-1 that exhibits uniform onset and progression of zosteriform lesions. The virulent H129 HSV-1 strain will be used for evaluating selected nanoviricides in this model. The uniform disease onset and progression make it an ideal model for comparative testing of various drug candidates that, the Company believes, can be expected to lead to a broad-spectrum anti-HSV antiviral treatment capable of attacking both HSV-1 and HSV-2. The company has developed a library of small chemical ligands that bind to the herpes virus envelope proteins. Using these ligands, a number of candidate nanoviricides that are capable of attacking the herpes virus have been developed. The Company believes that these nanoviricide drug candidates mimic the natural, common attachment function of the body's host cells using which both HSV-1 and HSV-2 cause infection.

NanoViricides, Inc. expected to report Fiscal Year 2010 results on October 14, 2010. This event was calculated by Capital IQ (Created on June 27, 2010).

NanoViricides, Inc. reported that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley. Treatment with one of the anti-Dengue nanoviricides(R) led to survival of 50% of the animals for the duration of study in the ADE model. In addition, animals treated with several anti-Dengue nanoviricides survived longer than the control animals treated with vehicle alone. This ADE model of infection is uniformly fatal in 100% of the infected animals within 5 days after infection. Dr. Harris is a leading researcher in the field of dengue viruses. Her group has developed a unique animal model for the most severe and potentially fatal form of Dengue virus infection in humans, Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS). The model emulates the "Antibody-Dependent Enhancement (ADE)" of Dengue virus infection in humans that is believed to lead to DHF/DSS.

NanoViricides Reports that its Drug Candidates Demonstrated Significant Inhibition of Herpes Virus Infection

Emerging Stock Report Initiates Independent Research Coverage on NanoViricides, Inc.

Nanoviricides® Anti-Ebola Results Presented at Annual Meeting of the American Society for Virology by USAMRIID Scientist

Liberty Analytics Co. Initiates Independent Research Coverage on NanoViricides, Inc.

Skymark Research Initiates Independent Research Coverage on NanoViricides, Inc.

Anti-Dengue Nanoviricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever

NanoViricides Reports that Antiviral Efficacy was Demonstrated Against Two Different HIV-1 Isolates in Cell Culture Studies, Corroborating Previous Findings in Animal Studies

NanoViricides Reports that Significant Efficacy was Achieved in Initial Studies on Dengue Virus

NanoViricides Files Quarterly Report

NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report

NanoViricides Signs anti-HIV Drug Candidate Testing Agreement with University of California, San Francisco

NanoViricides Announces a Herpes Virus Research Agreement With Professor Ken S. Rosenthal of Northeastern Ohio Universities College of Medicine

NANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

NanoViricides Raises $5M in Shelf Offering

NanoViricides Announces Trademark Registration for "Nanoviricides"

NanoViricides Invited to Present at the New York Biotechnology Association 2010 Annual Meeting

NANOVIRICIDES, INC. Files SEC form 10-K/A, Annual Report

NANOVIRICIDES, INC. Files SEC form 10-K/A, Annual Report

NANOVIRICIDES, INC. Files SEC form 10-Q/A, Quarterly Report

NanoViricides Announces Filing of Shelf Registration